GC Biopharma Develops Advanced Test to Detect Hunterase-Related Allergic Antibodies

GC Biopharma has introduced an innovative analytical method to identify drug-specific immunoglobulin E (IgE) antibodies that could cause allergic reactions in patients taking Hunterase, a medication used for Hunter syndrome. The South Korean biopharmaceutical firm revealed this development on October 13, with their research published in the Journal of Immunological Methods, a widely recognized scientific journal.

Hunter syndrome is a rare genetic condition resulting from a deficiency of enzymes needed to break down glycosaminoglycans (GAGs) in the body. One treatment method for this condition involves enzyme replacement therapy (ERT), which delivers the missing enzyme. However, protein-based therapies like ERT can sometimes provoke immune reactions in certain patients, causing the production of anti-drug antibodies (ADAs).

Among these, IgE antibodies are especially worrisome due to their potential to cause acute allergic reactions, such as difficulty breathing and low blood pressure. Therefore, accurately detecting these antibodies is crucial for evaluating treatment-related hypersensitivity and enhancing patient safety. Conventional antibody tests can only determine the presence of antibodies against a therapeutic drug but often fail to differentiate between specific antibody classes.

Identifying IgE antibodies is especially difficult because they are present in very low concentrations in the blood, making it hard to determine if an allergic reaction is directly linked to a specific medication. GC Biopharma's newly developed assay utilizes a high-sensitivity enzyme-linked immunosorbent assay (ELISA) to selectively detect IgE antibodies that specifically interact with Hunterase, even those present at low levels in patients' blood samples.

The company anticipates that this technology will enable more accurate assessments of the connection between Hunterase administration and possible allergic reactions. It could also facilitate better monitoring of immune responses during treatment and contribute to overall patient safety management. GC Biopharma envisions further applications of their analytical method for detecting drug-specific IgE antibodies and evaluating immunogenicity, or the capacity of a drug to provoke an immune response, not just for Hunterase but for other protein-based therapeutics as well.

Hong Jung-woon, head of the R&D Quality Management Unit at GC Biopharma, stated that the assay would serve as a foundation for more precise evaluation of drug-specific IgE-mediated hypersensitivity in patients receiving treatment for Hunter syndrome. He added that the company will continue to enhance its expertise in immunogenicity assessment and analytical technologies to improve pharmaceutical safety and patient care.